Analysis of Drug Formulary Exclusions from the Patient’s Perspective: 2023 Update

Sara Chea, Anne M. Sydor, Robert Popovian
doi: https://doi.org/10.1101/2023.11.01.23297921

Article Information

doi 
https://doi.org/10.1101/2023.11.01.23297921
History 
  • November 6, 2023.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Sara Chea, BS1,
  2. Anne M. Sydor, PhD2 and
  3. Robert Popovian, Pharm.D., MS3,*
  1. 1Pharm.D. Candidate, University of Southern California School of Pharmacy, and Health Policy Intern, Global Healthy Living Foundation
  2. 2Director of Research Development and Communication, Divisions of Patient-Centered Outcomes Research and Patient-Focused Economic and Policy Research, Global Healthy Living Foundation, Upper Nyack NY, United States
  3. 3Chief Science Policy Officer, Division of Patient-Focused Economic and Policy Research, Global Healthy Living Foundation, Upper Nyack NY, and Senior Health Policy Fellow, Progressive Policy Institute and Visiting Health Policy Fellow, Pioneer Institute, Boston MA, United States
  1. ↵*CORRESPONDING SENIOR AUTHOR:
    : Robert Popovian rpopovian{at}ghlf.org
Back to top
Posted November 06, 2023.
Download PDF
Data/Code
Email
Analysis of Drug Formulary Exclusions from the Patient’s Perspective: 2023 Update
Sara Chea, Anne M. Sydor, Robert Popovian
medRxiv 2023.11.01.23297921; doi: https://doi.org/10.1101/2023.11.01.23297921
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area